All posts by imreal

Rigicon and Rush University’s Prof. Laurence Levine Unveil Groundbreaking Surgical Tool


According to Dr. Levine “the HL-Levine Combo Prosthesis Tool facilitates easier dilation and penile implant insertion, helping to minimize potential surgical complications and promote better postoperative outcomes

Rigicon, Inc. a leading global innovator of prosthetic urology devices and solutions based in NY proudly announces the launch of the HL-LEVINE Combo Prosthesis Tool. This game-changing surgical tool is the newest innovative product designed and manufactured by Rigicon.

A global leader in prosthetic urology products, Rigicon works closely with leading prosthetic urology surgeons worldwide to create innovative, efficient, and patient-friendly devices. The new HL-LEVINE Combo Prosthesis Tool represents Rigicon’s commitment to innovation via collaboration with global physician partners. Dr. Huseyin Luleci and Dr. Laurence Levine, both world-renowned prosthetic urology surgeons, worked together to create this innovative combination surgical tool. The surgical tool is a combination HL dilator tool and traditional Furlow instrument both used for penile implant surgery. This new tool was designed to help facilitate better patient outcomes by decreasing operating time and eliminating the need to switch between the Furlow and HL dilator during the implant procedure.

“By merging these two key devices, the HL-LEVINE Combo Prosthesis Tool brings enhanced efficiency and simplicity to urological surgery,” said Dr Luleci. “This is an important leap forward in making complex procedures more manageable and, importantly, reducing the patient’s time in the operating room.”

According to Dr. Levine “the HL-Levine Combo Prosthesis Tool facilitates easier dilation and penile implant insertion, helping to minimize potential surgical complications and promote better postoperative outcomes.” By leveraging the design features of the two individual tools, the HL-LEVINE Combo Prosthesis Tool provides an innovative new option for surgeons to utilize during the implant procedures.

Rigicon is a global leader in prosthetic urology with products currently available in over 50 countries. A full list of products can be found on the company’s website at http://www.rigicon.com. This groundbreaking new surgical tool represents a new benchmark in the evolution of urological devices maintaining Rigicon’s position as a global leader of innovative prosthetic urology products in this important healthcare sector.

About Rigicon

Rigicon, based in Ronkonkoma, NY, is a pioneering company specializing in the design, development, and manufacturing of innovative urology devices. Our mission is to enhance the quality of patient care with our world-class products, which are developed in close collaboration with top surgeons worldwide. We remain committed to our mission to provide solutions that improve the quality of life for patients around the globe.

Share article on social media or email:

Non-Surgical Rhinoplasty Expert, Dr. Alexander Rivkin, Presented at the Vegas Cosmetic Surgery & Aesthetic Dermatology Multi-Specialty Aesthetic Conference


News Image

“It was an honor to help lead and participate in this prestigious conference, which is always a great learning experience for attendees,” says Dr. Alexander Rivkin.

The well-attended Vegas Cosmetic Surgery & Aesthetic Dermatology Multi-Specialty Aesthetic Conference (VCS) recently took place on June 8-10, 2023, at the Bellagio Convention Center in Las Vegas, NV. VCS is the leading, multispecialty conference incorporating both surgical and nonsurgical content. The conference was guided by experts with a mission to educate others for the advancement of aesthetic medicine and surgery. Dr. Alexander Rivkin and fellow leaders in the world of aesthetic surgery shared new techniques, emerging trends and insight. At this year’s conference, he chaired and moderated various presentations with panels of international experts that discussed how to achieve subtle, natural transformative aesthetic results without overfilling or overtreating. The panel conversations that Dr. Rivkin led were very informative, as there has been a considerable shift in this area of non-surgical plastic surgery, which has moved away from an overdone look to naturally refreshed results. The sessions also focused on reversing overdone results and the newest celebrity trends, such as stopping the overfilling of faces and dissolving excessive filler.

At his practice, RIVKIN Aesthetics, Dr. Alexander Rivkin has focused on developing and perfecting non-invasive, non-ablative cosmetic treatments. He provides expertise in creating undetectable subtle facial transformations and is a true expert in the world of aesthetic surgery with excellent credentials and a superior level of training. Dr. Rivkin is widely known for pioneering and popularizing the non-surgical rhinoplasty procedure, and in 2020 published the largest statistically comprehensive study on non-surgical rhinoplasty in medical literature. Dr. Rivkin has authored numerous peer-reviewed journal articles and book chapters on non-surgical cosmetic treatments. He frequently trains physicians from all over the world on optimizing advanced injection techniques and serves as a lead investigator on FDA and NIH clinical trials.

“It was an honor to help lead and participate in this prestigious conference, which is always a great learning experience for attendees,” says Dr. Alexander Rivkin.

More about Dr. Alexander Rivkin:

Dr. Rivkin is a facial aesthetic specialist and an assistant clinical professor at the David Geffen / UCLA School of Medicine. He received his undergraduate degree from Columbia University, medical degree from the Yale University School of Medicine and completed his residency in Otolaryngology/ Head and Neck Surgery at the University of California San Diego School of Medicine. Dr. Rivkin divides his time between patient care, clinical research, physician education, media appearances and lectures throughout the world. RIVKIN Aesthetics is located at 435 N Roxbury Dr #100 in Beverly Hills, CA 90210 and 11645 Wilshire Blvd., Suite 800 in Los Angeles, CA. For more information, please visit http://www.westsideaesthetics.com or call 310-443-5273.

Share article on social media or email:

Mediaplanet and the American Lung Association Are Teaching People How to Breath Better


News Image

According to the American Lung Association, more than 34 million Americans live with a chronic lung disease like asthma and COPD, which includes emphysema and chronic bronchitis.

This campaign will look to educate and support those at-risk and living with a chronic lung disease on how to prevent, treat and better their quality of life.

The print component of “Better Breathing” was distributed within USA TODAY on May 31st, 2023 in New York, Los Angeles, Denver, Chicago, Washington DC, Philadelphia/ Baltimore, Pittsburgh, Cleveland, North/Central Florida, South Florida, Dallas, St. Louis/Kansas City, Seattle, Detroit, Cincinnati, San Francisco, and Minneapolis markets, with a circulation of approximately 150,000 copies and an estimated readership of 450,000. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: https://issuu.com/mediaplanet_usa/docs/better_breathing_issuu

Harold Wimmer, National President and CEO, American Lung Association shares 5 ways to love your lungs.

“While there are things that impact our lung health daily, like secondhand smoke, pollution, and respiratory infections, there are actions we can take to keep our lungs healthy.

1.    Stop smoking and vaping: If you smoke cigarettes or vape, the best thing you can do for your lungs is to start your journey to quit. Experts recommend combining counseling and FDA-approved quit medication for the best chances of quitting smoking and vaping for good.

2.    Get all recommended respiratory vaccines: Illnesses like the flu, COVID-19, and pneumococcal pneumonia can have a serious impact on your lungs, so it is critical to make sure you are up to date on all vaccinations.

3.    If you are eligible, get screened for lung cancer: If you smoke or used to smoke, talk to your healthcare provider about lung cancer screening. Learn if you are eligible at SavedbytheScan.org.

4.    Exercise to maintain healthy lungs: When you are physically active, your heart and lungs work together to supply the additional oxygen your muscles demand. As your physical fitness improves, your body becomes more efficient at getting oxygen into the bloodstream and transporting it to the working muscles.

5.    Do your part to improve air quality: Air pollution impacts people living with lung disease but can also cause lung cancer. You can protect your own health by checking daily air pollution forecasts on AirNow.gov, and you can reduce your contributions to air pollution by walking or biking instead of driving and not burning trash or leaves.

As part of our mission to ensure all Americans breathe easier, we are inviting companies, consumers, and lung health champions everywhere to join our Lung Love campaign.”

This campaign was made possible with the support of the American Lung Association, Allergy & Asthma Network, Respiratory Health Association, Lung Cancer Research Foundation, Scout, GO2 Foundation, National Partnership for Healthcare and Hospice Innovation, National Radon Safety Board, and National Heart, Lung, and Blood Institute.

About Mediaplanet

Mediaplanet specializes in the creation of content marketing campaigns covering a variety of industries. We tell meaningful stories that educate our audience and position our clients as solution providers. Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse. Our award-winning stories have won the hearts of countless readers while serving as a valuable platform for brands and their missions. Just call us storytellers with a purpose. Please visit http://www.mediaplanet.com for more on who we are and what we do.

Press Contact:

Joanna Tronina

(646) 619-3516

Joanna.tronina@mediaplanet.com

Share article on social media or email:

Pharmaceutical Portfolio Planning with Dr. Wendy Cheung, Interview Special by Xtalks


News Image

Portfolio planning involves several steps, which include the assessment of unmet needs in the space, prioritization, portfolio analysis and risk assessment among others.

Portfolio planning and management is an integral part of the drug development process. Strategic decision-making is critical when determining which drugs to prioritize for development, and for building a robust pipeline for a specific indication or class of drugs. These decisions are key in the path to commercial success and most importantly, getting effective treatments to patients.

Only ten to 20 percent of drugs that make it through the development process end up getting approved and this has remained unchanged for the past several decades. While the COVID-19 pandemic helped the industry and regulatory bodies recognize how drug development can be effectively accelerated, there is still a lot of work to do in achieving better drug approval timelines and rates of success.

Portfolio planning involves several steps, which include the assessment of unmet needs in the space, prioritization, portfolio analysis and risk assessment among others. Many of these steps require continued strategic planning and decision-making throughout the development life cycle of a product and/or portfolio.

In this article, Xtalks spoke with Dr. Wendy Cheung, a leader in the strategy and product planning space, to gain insights into pharmaceutical portfolio planning. Dr. Cheung is the Global Head of Oncology Strategy New Product Planning and Operations Specialty Care at Sanofi Genzyme.

Dr. Cheung shared some of the current considerations and challenges in portfolio planning and how they can be tackled. She also described the keys to a successful portfolio and product launch, which include strategic decision-making and engaging different stakeholders early in the process, from investigators and regulatory bodies to patients, caregivers and advocacy groups. Dr. Cheung also discussed her journey as a leader in the product planning space as well as tips and advice for emerging leaders.

For more information and to read the full article featuring Dr. Wendy Cheung, visit: Pharmaceutical Portfolio Planning in Today’s Drug Development Climate.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Ayesha Rashid

Tel: +1 (416) 977-6555 x272

Email: arashid@xtalks.com

Share article on social media or email:

ServiconCares Committed to Supporting and Advocating for Mental Health Awareness


News Image

We know providing personal hygiene-related products isn’t the answer to the homelessness and mental health crises. But it is a small way to reach out to people struggling in the communities where we work and live to let them know we are here and care, not only in May but year-round.

To highlight Mental Health Awareness Month, ServiconCares, the philanthropic arm of Servicon, Southern California’s leading hospital environmental services (EVS) provider and commercial cleaning services company, filled and donated 200 bags of personal products. The bags were donated through nonprofits to help people in the community who are homeless or otherwise struggling through a transitional phase of life.

Hygiene for Improved Mental Health

35 Servicon staff volunteered on May 15, filling bags with products donated by Servicon. The bags included items nonprofits cited as most useful for people who are homeless and others in need, such as toothbrushes and toothpaste, soap, feminine hygiene products, hydration pads, socks, and even some long-lasting, allergen-free snacks. Servicon volunteers stuffed and delivered 200 bags. The donations were split between Maple Counseling Center and the LGBTQ Center in South Los Angeles, two nonprofits that serve the local communities.

“Mental health is essential to overall well-being and can be negatively impacted by a person’s physical circumstances,” says Servicon President and CEO Laurie Sewell. “We know providing personal hygiene-related products isn’t the answer to the homelessness and mental health crises. But it is a small way to reach out to people struggling in the communities where we work and live to let them know we are here and care, not only in May but year-round.”

The company has implemented several programs recently aimed at safeguarding the mental health of its employees, including providing an Employee Assistance Program (EAP) that goes beyond mental health insurance benefits, free access to trained therapists, childcare and eldercare assistance, and time management and financial literacy courses.

Help Throughout the Year

ServiconCares acts on its purpose, “to elevate the industry and create healthy environments for people to thrive,” by giving back to the community in May and throughout the years. In recent months, the company has partnered with local nonprofits, sponsoring several events in the last few months, including the Food Finders’ annual Stomp Out Hunger, a tree planting event with the TreePeople, the Walk for Kids to benefit the Ronald McDonald House Charities, and a women’s networking brunch held at Servicon’s headquarters in honor of Women’s History Month—to name but a few.

About Maple Counseling

The mission of Maple Counseling is to provide low-cost comprehensive mental health services to individuals of all ages, couples, and families and training of graduates and postgraduates for licensure in the mental health field. For more information, visit maple4counseling.org.

About the Los Angeles LBGT Center

The Los Angeles LBGT Center provides services for more LGBTQ people than any other organization worldwide, offering programs, services, and global advocacy spanning four broad categories: health, social services and housing, culture and education, and leadership and advocacy. The center provides housing for homeless youth and affordable housing for seniors, helps transgender people find employment, and offers legal support for asylum seekers. For more information, visit lalgbtcenter.org.

About Servicon, California’s Leading EVS and Commercial Cleaning Services Provider

Celebrating its 50th anniversary this year, Servicon is a leading hospital EVS and commercial services cleaning company specializing in hospital EVS, life sciences, aerospace, and facility maintenance. At Servicon, we live by our purpose to elevate the industry and provide healthy environments for people to thrive. As a privately held, women-owned and operated company, we work and live by our vision of creating a better working future, which includes a more sustainable one. To learn more about Servicon, including our sustainability efforts and services, visit servicon.com or contact us.

Share article on social media or email:

RF Technologies® Attends AWHONN 2023 in New Orleans, LA, Booth 1009


“We believe that our solutions and recent EMR software integration update can help healthcare facilities increase value-added time and provide a safer and more secure environment.” Jeff Aulds, VP of Hospital Sales

RF Technologies (RFT), a leading provider of safety and security solutions for the healthcare industry, is pleased to announce their attendance at the AWHONN 2023 Trade Show. The event will take place from June 17 to June 21 at the Ernest N. Morial Convention Center in New Orleans, LA. RFT will be exhibiting at booth 1009.

At the event, RFT will showcase their freshly released Enterprise Software 7.2, which now includes EMR integration with EHR systems, such as Epic and Cerner. RFT’s innovative safety and security solutions include their fully integrated Safe Place® Solution that encompasses Infant and Pediatric Security, Staff Protection, and Equipment Locating. The Safe Place solution is designed to provide a safe and secure environment and value-added time that allows care staff more time with infants, children, and other patients, ensuring that they are protected from harm and are never separated from their parents or caregivers.

“We are thrilled to be a part of AWHONN 2023,” said Jeff Aulds, VP of Hospital Sales. “This event is an excellent opportunity for us to showcase our latest software and solution innovations in safety and security technology, and to connect with healthcare professionals from all over the world.”

In addition to showcasing their comprehensive solutions, RFT will also be hosting a series of presentations and demonstrations at their booth throughout the event. These presentations will provide attendees with an in-depth look at RFT’s technology and how it can be used to improve safety and security in healthcare facilities.

“We are excited to connect with healthcare professionals at AWHONN 2023 and to share our knowledge and expertise with them,” said Aulds. “We believe that our solutions and recent EMR software integration update can help healthcare facilities increase value-added time and provide a safer and more secure environment.”

RFT has been providing safety and security solutions to healthcare facilities for over 35 years and is dedicated to improving the safety and security of healthcare facilities worldwide. To learn more about RFT and their solutions, visit booth 1009 at AWHONN 2023.

For questions or inquiries, please contact the RFT marketing department at marcomm@rft.com.

About RF Technologies

RFT is a turn-key manufacturer and provider of life safety solutions for the senior living, healthcare, education, and hospitality markets. With 11,000+ installations since their founding in 1987, RFT is a collaborative partner in designing custom-configured solutions that meet each customer’s needs and reduce their liabilities. The RFT family of solutions includes CODE ALERT® nurse call, fall detection, and wander management, SAFE PLACE® patient, staff, and asset protection, HELP ALERT® staff duress, and SENSATEC® fall management products.

Share article on social media or email:

AvevoRx Reaches Limited Distribution Agreement for Gammaplex® IG Treatment


Gammaplex gives us more treatment options for our IG patients and prescribers,” said Justin Dent, National Director of Pharmacy Operations. “Having both concentrations gives us more options to manage side effects and tailor each patient’s therapy to their specific needs.

AvevoRx, a national, independent provider of specialty infusion pharmacy services, has announced a limited distribution agreement for Gammaplex®, an immune globulin (IG) product from Bio Products Laboratory (BPL). AvevoRx currently stocks Gammaplex and is dispensing to qualified patients.

“Our top priority as a company is ensuring our patients have safe and streamlined access to the treatments they need. Expanding our portfolio helps us meet that need and adding Gammaplex to the mix is a great step for us,” said Eric Hill, co-founder of AvevoRx. “We appreciate the trust that partners like BPL have in us to deliver that care.”

“Our experience with Gammaplex, and its high degree of tolerability, gives us more treatment options for our IG patients and prescribers,” said Justin Dent, National Director of Pharmacy Operations for AvevoRx. “Additionally, having both a 5- and 10-percent concentration gives our clinicians more options to manage side effects and tailor each patient’s therapy to their specific needs.”

Gammaplex is an IG product for patients with primary humoral immunodeficiencies (PI), a group of disorders that limit the body’s ability to produce antibodies and fight infections. It harnesses human antibodies, derived primarily from human plasma, to help boost the immune system and prevent infections. Multiple IG products are available in the U.S. The agreement with BPI allows AvevoRx to dispense a larger portfolio of IVIG products.

Gammaplex is a registered trademark of Bio Products Laboratory Limited, a Kedrion company.

Visit AvevoRx.com for more information.

About AvevoRx

AvevoRx is a bespoke, independent provider of specialty infusion pharmacy services. The company focuses on the highest-quality, personalized care customized to patients facing various complex, chronic disorders. Treatments are made available via specialized pharmacy locations, field nurses, and additional support staff throughout the United States. AvevoRx also provides acute infusion therapies for patients with short-term therapeutic needs on a regional basis. Privately held, the company was founded in 2021 by a small group of industry veterans with a combined experience of more than 130 years. AvevoRx is headquartered in North Carolina. To learn more, visit http://www.AvevoRx.com or follow us on Instagram or LinkedIn.

Share article on social media or email:



Study Finds Significantly More Adults Living with Diabetic Retinopathy in the United States than Previously Estimated


Data from new study, ‘Prevalence of Diabetic Retinopathy in the US in 2021’ study shows estimated 9.6 million people in the United States had eye disease diabetic retinopathy.

“The number of diabetes cases in America continues to grow, and with that, so are the damaging effects on vision. It is our hope that this new data will guide us to successful interventions and improved outcomes for those with diabetes and their families.”-Jeff Todd, Prevent Blindness.

A new study published today in JAMA Ophthalmology, “Prevalence of Diabetic Retinopathy in the US in 2021,” found that in 2021, an estimated 9.6 million people in the United States (26.4 percent of those with diabetes) had diabetic retinopathy (DR), and 1.84 million people (5.1 percent of those with diabetes) had vision-threatening diabetic retinopathy (VTDR). The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004. VTDR has also almost doubled since last estimated in 2004.

The study is the first of its kind to estimate the prevalence of DR and VTDR in people younger than 40 years. In the youngest age group, ages 0 to 24 years, more than 1 in 10 people with diabetes had DR, which increased to nearly 1 in 5 among people with diabetes ages 25 to 39 years.

Diabetic retinopathy occurs when small blood vessels leak and bleed in the retina. The retina is the layer of cells lining the back wall inside the eye that senses light and sends signals to the brain for vision. Early detection and treatment can reduce the risk of vision loss from this potentially blinding eye disease.

The ‘Prevalence of Diabetic Retinopathy in the US in 2021’ study was authored by researchers from the Centers for Disease Control and Prevention’s (CDC) Vision Health Initiative, NORC at the University of Chicago (NORC), and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington (Seattle), with support from Prevent Blindness, the nation’s oldest eye health and safety nonprofit organization.

“The national increase of diabetes over the last two decades has likely impacted the number of people living with serious complications like diabetic retinopathy,” said CDC epidemiologist Elizabeth Lundeen, PhD, MPH. “This study provides new state and county level prevalence estimates that the health care and public health communities can use to inform screening and early interventions for optimal vision health.”

Abraham Flaxman, PhD, added: “In this work, we brought together data from all the relevant sources in the CDC’s Vision and Eye Health Surveillance System to triangulate between multiple measurements and make estimates that no single source could provide alone.”

Additional key findings from the study include:


  • Approximately 1 in 4 Americans ages 40 and older with diabetes have DR.
  • These new estimates include the prevalence of DR and VTDR in people younger than age 40 years. Past prevalence estimates were only for the US population aged 40 and older.
  • VTDR prevalence rates are higher for Black (8.7 percent) and Hispanic (7.1 percent) individuals than White individuals (3.6 percent). Thus, a higher percentage of Black and Hispanic individuals with diabetes are at risk for vision loss compared to their White counterparts.
  • The prevalence of both DR and VTDR varied widely by U.S. state and county. After standardizing by age, sex/gender, and race/ethnicity, rates of DR among persons with diabetes ranged from a low of 21.2 percent in Nevada to a high of 34.2 percent in Hawaii.
  • Prevalence of DR and VTDR among people with diabetes increased substantially with age but then decreased in the older age groups, likely because DR and VTDR are markers for more severe diabetes, which can lead to early mortality.

“This study demonstrates the value of vision surveillance, which allows us to monitor emerging trends in vision threatening conditions like diabetic retinopathy,” said David B. Rein, Ph.D., Program Area Director for NORC at the University of Chicago’s Public Health Analytics Program and one of the study’s co-authors. “The information provided in this study can be used at the national, state, and county level to understand the burden of diabetic retinopathy and to design interventions to help people living with the condition preserve their vision.”

Study estimates were developed using data from CDC’s Vision and Eye Health Surveillance System (VEHSS). The VEHSS leverages new and existing data sources to help health professionals, researchers, policy makers, and patients understand the scope of vision loss, eye disorders, and eye care services in the United States. Detailed estimates of DR and VTDR at the national-, state-, and county-level stratified by age group, sex/gender, and race/ethnicity can be accessed online at the VEHSS website (https://www.cdc.gov/visionhealth/vehss/estimates/index.html).

Prevent Blindness serves as an education and communications partner for the VEHSS. For diabetes patients and their care partners, Prevent Blindness offers a wide variety of user-friendly resources in English and Spanish, including downloadable fact sheets, patient educational videos, and a listing of eye care financial assistance resources.

For healthcare professionals, community health educators, and diabetes educators, Prevent Blindness provides the newly redesigned Diabetes + The Eyes educational toolkit. This free program includes an educator course with PowerPoint presentations and scripts, fact sheets, and social media graphics.

“The number of diabetes cases in America continues to grow, and with that, so are the damaging effects on vision,” said Jeff Todd, president and CEO of Prevent Blindness. “It is our hope that this new data will guide us to successful interventions and improved outcomes for those with diabetes and their families.”

For more information on the “The Prevalence of Diabetic Retinopathy in the United States In 2021” study or the VEHSS, visit https://www.cdc.gov/visionhealth/vehss/. Or visit the Prevent Blindness page at https://PreventBlindness.org/DR-prevalence-vehss.

For information on diabetes-related eye diseases, please visit https://preventblindness.org/diabetes/.

About the Vision Health Initiative

CDC’s Vision Health Initiative (VHI) works to improve vision health in the U.S. through collaborations with state and national partners to strengthen science and develop interventions that promote eye health and prevent vision loss and blindness in groups at high risk. VHI also seeks to address risk factors like glaucoma, reduce disparities in vision loss and eye disease, and improve health and quality of life for people with vision loss. VHI designs and implements public health surveillance at the state and national level, supports applied public health research, and promotes the dissemination of evidence-based vision health interventions. In collaboration with state and community partners, VHI works to integrate vision health activities into broader public health strategies and interventions. For more information, visit http://www.cdc.gov/visionhealth.

About NORC at the University of Chicago

NORC at the University of Chicago conducts research and analysis that decision-makers trust. As a nonpartisan research organization and a pioneer in measuring and understanding the world, we have studied almost every aspect of the human experience and every major news event for more than eight decades. Today, we partner with government, corporate, and nonprofit clients around the world to provide the objectivity and expertise necessary to inform the critical decisions facing society.

http://www.norc.org

About the Institute for Health Metrics and Evaluation

The Institute for Health Metrics and Evaluation (IHME) is an independent global health research organization at the University of Washington School of Medicine that provides rigorous and comparable measurement of the world’s most important health problems and evaluates the strategies used to address them. IHME is committed to transparency and makes this information widely available so that policymakers have the evidence they need to make informed decisions on allocating resources to improve population health.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at PreventBlindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

###

Mobile Dental Clinic to Provide Dental Care for New Hampshire Medicaid Patients in Colebrook


Mobile Dental Solutions - mobile health unit - Solvere Health

“We are excited to bring our expertise in group health events and mobile healthcare delivery to New Hampshire. Our mission is to expand healthcare access and improve health equity in underserved communities – rural ones in particular.”

Solvere Health, a provider of intelligent and sustainable healthcare solutions for underserved communities, announced that it will hold a mobile dental clinic on June 24 & 25 at Upper Connecticut Valley Hospital at 181 Corliss Lane, Colebrook, New Hampshire. The clinic is a joint effort by Solvere Health, Northeast Delta Dental, and DentaQuest. The clinic is exclusively for New Hampshire Medicaid patients ages 21+.

The New Hampshire Department of Health and Human Services recently announced the launch of the New Hampshire Smiles Adult Program, which provides comprehensive dental coverage to adults ages 21+ with insurance coverage through New Hampshire Medicaid. The Colebrook mobile dental clinic will be held in a mobile medical unit – one of 50 in Solvere Health’s state-of-the-art mobile health fleet. It is a fully equipped dental office engineered to support comprehensive care by an expert dentist and dental hygienist team. Patients can access diagnostic, preventative, and operative services, including:

  • diagnostic exams
  • x-rays, fillings
  • extractions
  • restorations
  • tooth pain management & antibiotics.

Medicaid patients with limited mobility are welcome, as Solvere Health’s mobile medical units are designed with accessibility accommodations like wheelchair ramps.

Edward Lorch, Solvere Health’s CEO, said, “We are excited to bring our expertise in group health events and mobile healthcare delivery to New Hampshire. Our mission is to expand healthcare access and improve health equity in underserved communities – rural ones in particular. This is our sixth mobile dentistry event in New Hampshire, and we are proud to be a part of this important initiative.”

Adult patients ages 21+ should call 877-248-6684 to make an appointment. At their appointment, patients should have their DentaQuest ID card & personal ID.For more information about Solvere Health and its services, visit solverehealth.com.

Media Contact:

Jackie Skorvanek, Chief of Staff

Solvere Health

Phone: 1-833-SOLVERE

Email: jskorvanek@solverehealth.com

About Solvere Health:

Working with state, federal, institutional, and corporate partners, Solvere Health brings a business discipline to health challenges across the United States through onsite mobile and digital healthcare solutions. Deploying a team of highly motivated, accountable problem solvers, we stand up sustainable, end-to-end programs in rapid response to group health events, disaster relief, and underserved rural populations. Our efficient approach combines exacting strategic planning, comprehensive compliance management, unparalleled logistics, state-of-the-art mobile healthcare technology, and emerging digital health applications.

Share article on social media or email:

New Aseptico® 1070 Series Implant Motor is Designed to Streamline and Simplify Workflow


The new Aseptico® 1070 Series Implant Motor offers the implant dentist ease-of-use, power, and precision, at an affordable price.

The new Aseptico® 1070 Series Implant Motor offers the implant dentist ease-of-use, power, and precision, at an affordable price.

“The New 1070 Series Implant Motor is like the sports car of implant motors — it has plenty of power and allows the dentist to have precise control of speed, torque, direction, irrigation flow, and presets, at the touch of a fingertip or tap on the multifunction foot control.”

Aseptico Inc. announced today, the introduction of a new dental implant motor to its already extensive lineup of dental motor systems.

The new Aseptico® 1070 Series Implant Motor is a powerful and efficient tool designed to streamline dental implant procedures. With its compact size, intuitive interface, and multifunction foot control, this implant motor offers the clinician ease-of-use, power, and precision at an affordable price.

Aseptico Inc. is introducing the new 1070 Series implant motor in response to clinicians who have expressed a desire for a simple, powerful, streamlined dental motor system that can handle implant cases efficiently without unnecessary complexity.

“The new 1070 Series Implant Motor is like the sports car of implant motors — it has plenty of power and allows the dentist to have precise control of speed, torque, direction, irrigation flow, and presets, at the touch of a fingertip or tap on the multifunction foot control,” said Stuart Kazen, Director of Domestic Sales for Aseptico Inc.

Benefits of the new Aseptico® 1070 Series Implant Motor for dentists placing dental implants include:


  • Streamlines workflow: Osteotomy and implant placement are handled with ease using an available Mont Blanc 20:1 reduction handpiece.
  • User-friendly interface: The touchscreen display and intuitive user interface make it simple to adjust motor settings according to the dentist’s preferences.
  • Hands-free control: The multifunction foot control enables easy adjustment of speed, direction, irrigation flow, torque, and presets, enhancing efficiency and infection control.
  • Precise and powerful: The brushless 40,000 RPM motor delivers the power needed for accurate and efficient implant procedures.
  • Versatility: With the 1:1 setting (and available 1:1 straight handpiece attachment), the 1070 Series motor is also suitable for surgical and low-speed procedures.
  • Customization options: The eight programmable presets allow customization of motor settings based on preferred techniques.
  • Enhanced accuracy: The integrated handpiece calibration feature ensures speed and torque accuracy at the bur, providing consistent and reliable performance.
  • Compact and durable: The motor’s compact footprint and water-resistant chassis design make it suitable for various clinical environments.
  • Sustainability-focused: The Aseptico® 1070 Series implant motor utilizes autoclavable irrigation tubing, reducing waste and saving costs compared to single-use, disposable tubing.
  • Warranty and service: Aseptico offers a two-year motor warranty with dedicated service provided in the USA.

The retail price for the Aseptico® 1070 Series Implant Motor is only $3,550. As a special introductory offer during the dates of June 1–Aug 21, 2023, buyers will receive a free Mont Blanc 20:1 handpiece with each purchase of an Aseptico® 1070 Series Implant Motor. To learn more about the new Aseptico® 1070 Series Implant Motor and offer details, visit aseptico.com.

About Aseptico, Inc.

Headquartered in Woodinville, WA, Aseptico Inc. is a global leader in the design and manufacture of broad range of dental equipment, including dental motors, mobile and portable dental equipment, and other innovative products that help dentists perform more effectively. Aseptico® dental motors for oral surgery, dental implant placement, endodontics, and restorative dentistry are made in the USA and have earned numerous industry accolades and a worldwide reputation for legendary performance and reliability. The US military, public health outreach programs and humanitarian dental groups around the world rely on Aseptico® mobile & portable dental equipment. The Aseptico® Global Dental Catalog features innovative and practical products that deliver distinct advantages for dental professionals including HandiDam® Pre-Framed Dental Dam, Penguin II and Penguin RFA Implant Stability Monitors, Spotter Smart Implant Detector, Calaject™ computer-assisted dental anesthesia, Aseptico® Equipment Trolleys and more. For more information and to browse available products visit Aseptico.com.

Share article on social media or email: